TICKERNERD
Menu
TVRDHealthcare · Biotechnology

TVRD Stock Forecast: Tvardi Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$1.10
+1.85% on the day

The 9 Wall Street analysts covering Tvardi Therapeutics, Inc. hold a median 12-month price target of $10 — +809.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 7 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$15.2M
Ticker Nerd rank
32 / 100
Median analyst target
$10
Analysts covering
9
Revenue$0.0
Operating income−$6.6M
Net income−$6.5M
Free cash flow−$9.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.0%
1M
−42.4%
YTD
−74.4%
1Y
−97.3%
From 52W high
−97.4%
From 52W low
+3.8%
$1
$43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TVRD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tvardi Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Oct 2026
32 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
90
Issuance
60
Revisions
60
Accruals
46
Volatility
36
Growth
33
Quality
30
Momentum
20
Value
12

Size (90): Smaller than most of the companies we track.

Value (12): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TVRD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TVRD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26TVRDHigh $14Median $10Low $3

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
7 Buy1 Hold1 Sell
Low $3Median $10High $14

The green dot is the last close — the median target sits +809.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 Sept 2026LUCID CAPITAL MARKETSAssumesBuy$14
30 July 2026BTIGMaintainsBuy$15 → $5.00
30 July 2026BTIGMaintainsBuy—
8 July 2026Raymond JamesUpgradeOutperform—
8 July 2026Raymond JamesUpgradeOutperform$10
7 July 2026BTIGReiteratesBuy—
7 July 2026BTIGReiteratesBuy$15
8 June 2026HC Wainwright & Co.InitiatesBuy—
20 Apr 2026BarclaysDowngradeUnderweight—
1 Apr 2026BarclaysMaintainsEqual-Weight—
1 Apr 2026BTIGReiteratesBuy—
1 Apr 2026Piper SandlerMaintainsNeutral—
14 Oct 2025Raymond JamesDowngradeMarket Perform—
13 Oct 2025BarclaysInitiatesOverweight—
13 Oct 2025BTIGMaintainsBuy—
14 July 2025Raymond JamesInitiatesOutperform—
11 July 2025Cantor FitzgeraldInitiatesOverweight—
12 June 2025Piper SandlerInitiatesOverweight—
21 May 2025OppenheimerInitiatesOutperform—
28 Apr 2025Jones TradingInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TVRD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TVRD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, Tvardi Therapeutics, Inc. returned −97.3% against +17.4% for the S&P 500, dividends included.

TVRD vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26TVRDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TVRD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
3
Fundamentals

Tvardi Therapeutics, Inc. (TVRD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.5×

Cheaper than 80% of US stocks

Price / sales
—
Price / book
0.7×

Cheaper than 80% of US stocks

EV / EBITDA
0.0×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−126.2%

Higher than 11% of US stocks

Return on assets
−55.5%

Higher than 7% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Tvardi Therapeutics, Inc. (TVRD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tvardi Therapeutics, Inc. has a market value of $15.2M and an enterprise value of −$414K.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$26.1M.

  • Diluted earnings per share, trailing twelve months: $−2.79.

  • Free cash flow in the twelve months to 30 June 2026: −$25.0M.

  • Shares outstanding: 9.4M.

  • Trailing P/E: −0.5×; forward P/E: −0.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Tvardi Therapeutics, Inc. employs 12 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

TVRD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TVRDTvardi Therapeutics, Inc.$15.2M
32
KPTIKaryopharm Therapeutics, Inc.$14.5M
61
KTTAPasithea Therapeutics Corp.$14.8M
15
NIKINiki Biosolutions, Inc.$14.5M
11
HINDVyome Holdings, Inc.$14.3M
64
CLRBCellectar Biosciences, Inc.$14.3M
27
DAREDaré Bioscience, Inc.$15.3M
31

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tvardi Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TVRD news & analysis

New Preclinical Data Further Support Potential for Tvardi's STAT3 Inhibitors in Ulcerative Colitis (UC)

GlobeNewsWire · 24 Sept 2026positive

Tvardi Therapeutics announced the publication of preclinical data in the International Journal of Molecular Sciences evaluating its STAT3 inhibitors for ulcerative colitis. In a chronic colitis model, the oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma at pharmacologically relevant levels and modulated STAT3-driven disease biology. The findings span multiple preclinical UC models and support the rationale for advancing TTI-109, the company's next-generation STAT3 inhibitor.

Why it matters — The preclinical data strengthen the scientific foundation for Tvardi's STAT3 inhibitor program in ulcerative colitis, a key potential indication for its TTI-109 candidate.

Tvardi Therapeutics to Participate in Upcoming Investor Events

GlobeNewsWire · 26 Aug 2026neutral

Tvardi Therapeutics announced that company management will participate in several upcoming investor events. The clinical-stage biopharmaceutical company, which develops oral small-molecule therapies targeting STAT3 for inflammatory and proliferative diseases, made the announcement on August 26, 2026.

Why it matters — A TVRD watcher would care because management's participation in investor events provides opportunities for the company to present its pipeline and engage with investors.

Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis Transcript

Seeking Alpha · 19 Aug 2026neutral

Tvardi Therapeutics, Inc. (TVRD) is the subject of a transcript in which the company discusses its TTI-109 development program and related data in ulcerative colitis, as reported by Seeking Alpha.

Why it matters — A TVRD watcher would care because the transcript provides insight into the company's TTI-109 development program and its data in ulcerative colitis.

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

GlobeNewsWire · 14 Aug 2026positive

Tvardi Therapeutics announced its second quarter 2026 results and provided a business update. The company reported topline healthy volunteer results for its next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability, and reductions in disease-relevant immune cell populations.

Why it matters — TVRD watchers would care because the TTI-109 topline data represent early clinical validation of the company's next-generation STAT3 inhibitor platform.

Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026

GlobeNewsWire · 12 Aug 2026neutral

Tvardi Therapeutics announced it will host a key opinion leader webinar on August 19, 2026, featuring Dr. Randy Longman of Weill Cornell Medicine, to discuss the current ulcerative colitis treatment landscape and persistent unmet needs. The event will include new data from Tvardi and a review of Phase 1 healthy volunteer results supporting the potential of TTI-109 in ulcerative colitis.

Why it matters — TVRD watchers would care because the webinar highlights new data and clinical progress on TTI-109, one of the company's key investigational candidates targeting STAT3 in inflammatory disease.

FAQ

Frequently asked questions about TVRD stock

What is the TVRD stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Tvardi Therapeutics, Inc. have a median 12-month price target of $10, with estimates ranging from $3 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TVRD stock a buy right now?

Of the 9 analysts covering Tvardi Therapeutics, Inc., 7 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Tvardi Therapeutics, Inc. 32 out of 100 across roughly 4,600 US stocks as at 7 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TVRD?

As at 7 Oct 2026, Tvardi Therapeutics, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).

Will TVRD stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +809.1% from the last close, and Ticker Nerd's factor model ranks Tvardi Therapeutics, Inc. 32 out of 100 as at 7 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TVRD stock forecast for 2030?

No analyst covering Tvardi Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TVRD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $14 over the next 12 months.

How has TVRD stock performed over the past year?

Tvardi Therapeutics, Inc. returned -97.3% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tvardi Therapeutics, Inc. do?

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small-molecule therapies that target STAT3, a signaling pathway associated with inflammatory and proliferative diseases.

What is the latest news on TVRD?

The most recent item we track (GlobeNewsWire, 24 Sept 2026): "New Preclinical Data Further Support Potential for Tvardi's STAT3 Inhibitors in Ulcerative Colitis (UC)". Tvardi Therapeutics announced the publication of preclinical data in the International Journal of Molecular Sciences evaluating its STAT3 inhibitors for ulcerative colitis. In a chronic colitis model, the oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma at pharmacologically relevant levels and modulated STAT3-driven disease biology. The findings span multiple preclinical UC models and support the rationale for advancing TTI-109, the company's next-generation STAT3 inhibitor.

Company

About Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small-molecule therapies that target STAT3, a signaling pathway associated with inflammatory and proliferative diseases. The company’s current pipeline includes TTI-101, which is being studied for fibrosis-driven diseases such as idiopathic pulmonary fibrosis and hepatocellular carcinoma, and TTI-109, a next-generation oral STAT3 inhibitor in early clinical development. Tvardi Therapeutics concentrates on conditions with significant unmet medical need, positioning its research around disease areas where targeted therapies may address complex biological pathways. Based in Sugar Land, Texas, Tvardi Therapeutics serves the biotechnology market through a pipeline centered on precision, mechanism-based drug development.

CEO Dr. Imran Alibhai Ph.D. · 12 employees · United States · https://tvarditherapeutics.com